Tyra Biosciences, Inc.
CARLSBAD, CA · CIK 0001863127 · Biotech · Public
Oral small-molecule kinase inhibitor (dabogratinib) for skeletal dysplasia and urologic cancers
tyra.bio →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $200M
- 1 Form D · Feb 2024
- 32 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20232024202520262027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $199,999,934 |
Form D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1266 | MOLECULAR TECHNOLOGIES LABORATORIES LLC | — | — |
| 1267 | MARTINGALE LABS, INC. | — | — |
| 1268 | Monte Rosa Therapeutics, Inc. | — | $143M |
| 1269 | Tyra Biosciences, Inc. | — | $200M |
| 1270 | NEUROEPIGENIX, LLC | — | — |
| 1271 | Third Harmonic Bio | — | — |
| 1272 | BridgeBio Oncology Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026PRNewswire
Founders & Team
- Daniel BensenExecutive Officer
- Isan Chen, M.D.Director
- Alan FuhrmanExecutive Officer
- Todd Harris, Ph.D.Director · Executive Officer
- Gilla Kaplan, Ph.D.Director
- Nina KjellsonDirector
- Melissa McCracken, Ph.D.Director
- Robert MoreDirector
- Jake Simson, Ph.D.Director
- Sid Subramony, Ph.D.Director
- Hiroomi Tada, M.D., Ph.D.Executive Officer
- Rehan VerjeeDirector
Patents
- FGFR3 Inhibitor Compoundsapplication
- Methods Of Treating Solid Tumors Having Activation FGFR3 Gene Alterationsapplication
- Indazole Compoundsapplication
- Therapies With Ppar Agonists And FGFR4 Inhibitorsapplication
- Indazole Compounds As Kinase Inhibitorsapplication
- Indazole Compoundsgranted
- Indazole Compounds As Kinase Inhibitorsgranted
- Indazole Compoundsapplication
- Indazole Compounds As Kinase Inhibitorsgranted
- Aminopyrimidine Compounds And Methods Of Their Useapplication
- Aminopyrimidine Compoundsapplication
- Methods of Treating Children with Achondroplasiaapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.